Abstract:Background Adjuvant chemotherapy after radical resection of stage IIIA non-small-cell lung cancer (NSCLC) has quite poor outcomes. We aimed to investigate whether adjuvant erlotinib therapy improves 2-year disease-free survival compared with chemotherapy in epidermal growth factor receptor (EGFR) mutation-positive stage IIIA NSCLC. Methods In this randomised, open-label, phase 2 trial, eligible patients aged 18-75 years who had undergone complete (RO) resection of histologically or pathologically confirmed stage IIIA EGFR mutation-positive NSCLC and had not received any previous anticancer therapies were enrolled. Patients were randomly assigned (1:1) to receive either adjuvant erlotinib (150 mg once daily administered orally) or vinorelbine and cisplatin chemotherapy (four cycles of vinorelbine [25 mg/m(2) intravenously on days 1 and 8 of each 21-day cycle] plus cisplatin [75 mg/m(2) intravenously on day 1 of each 21-day cycle]). Randomisation was done by Simon's minimisation with a random element and was stratified by EGFR activating mutation type (exon 19 vs 21), histology (adenocarcinoma vs non-adenocarcinoma), and smoking status (smoker vs non-smoker). The primary endpoint in the unblinded intention-to-treat analysis was 2-year disease-free survival. This ongoing study is registered with ClinicalTrials.gov , number NCT01683175. Findings Between Sept 8, 2012, and May 21, 2015, 102 patients from 16 centres across China were enrolled and randomly assigned to receive erlotinib (n=51) or chemotherapy (n=51). Median follow-up was 33.0 months (IQR 17-8-43-1). 2-year disease-free survival was 81.4% (95% CI 69.6-93.1) in the erlotinib group and 44.6% (26 -9-62- 4) in the chemotherapy group (relative risk 1.823 [95% CI 1.194-2.784; p=0.0054). The difference in 2-year disease-free survival between the groups was 36.7% (95% CI 15 - 5-58- 0; p=0.0007). Adverse events of any grade occurred in 29 (58%) of 50 patients in the erlotinib group and 28 (65%) of 43 patients in the chemotherapy group. Grade 3 or worse adverse events occurred in six (12%) of 50 patients in the erlotinib group versus 11 (26%) of 43 in the chemotherapy group; the most common of these in the erlotinib group was rash (in two 14%1 of 50 patients) and in the chemotherapy group were decreased neutrophil count (in seven [16%] of 43 patients) and myelosuppression (in four [9%]). No treatment-related deaths were reported. Interpretation Adjuvant erlotinib improved 2-year disease-free survival in patients with EGFR mutation-positive stage IIIA NSCLC compared with chemotherapy, with a better tolerability profile. This study suggests that tyrosine kinase inhibitors could have a potentially important role as adjuvant therapy in EGFR mutation-positive stage IIIA NSCLC. However, this trial was a phase 2 study. Mature overall survival data are also needed. Ongoing studies will hopefully confirm the role of adjuvant EGFR tyrosine kinase inhibitor therapy in patients with NSCLC. Copyright (C) 2018 Elsevier Ltd. All rights reserved.

EP05.02-016 Aumolertinib after Adjuvant Chemotherapy/Radiotherapy in Stage Piiia-N2 Non-Small-Cell Lung Cancer with EGFR Mutation

EP07.05-17 Aumolertinib As Neoadjuvant Therapy for EGFR-mutated Non-Small Cell Lung Cancer: A Subcohort Analysis of the PURPOSE Trial

Icotinib Versus Vinorelbine/platinum As Adjuvant Therapy in Stage II-IIIA Non-Small Cell Lung Cancer with EGFR-mutations: A Multicenter, Randomized, Positive-Controlled, Phase 3, Indication-Expanding Study (EVIDENCE, CCTC-1501).

FP14.11 Icotinib Versus Chemotherapy As Adjuvant Treatment for Stage II–IIIA EGFR-Mutant NSCLC (EVIDENCE): A Randomized, Open-Label, Phase 3 Study

EP07.05-02 NEOEAST: A Phase II Study of Ensartinib As Neoadjuvant Therapy for Stage II-IIIB ALK-rearranged Non-small Cell Lung Cancer

P2.01-02 Neoadjuvant Targeted Therapy for Resectable ALK-fusion Locally Advanced Non-small Cell Lung Cancer

Efficacy and Safety of Aumolertinib Combined with or Without Chemotherapy As an Adjuvant Treatment for Stage II-IIIA Non-Small Cell Lung Cancer Following Complete Tumour Resection: the First Third-Generation EGFR-TKI Versus Chemotherapy Phase III Clinical Study (APEX).

OA 16.04 Efficacy and Safety of Erlotinib Vs Vinorelbine/Cisplatin As Adjuvant Therapy for Stage IIIA EGFR Mutant NSCLC Patients

Case Report: Aumolertinib as Neoadjuvant Therapy for Patients With Unresectable Stage III Non-Small Cell Lung Cancer With Activated EGFR Mutation: Case Series

Epidermal Growth Factor Receptor Inhibitors As Adjuvant Treatment for Patients with Resected Non-Small Cell Lung Cancer Harboring EGFR Mutation: a Meta-Analysis of Randomized Controlled Clinical Trials

A Retrospective Study of Stage I to IIIa Lung Adenocarcinoma After Resection: What Is the Optimal Adjuvant Modality for Patients With an EGFR Mutation?

Erlotinib Versus Vinorelbine Plus Cisplatin As Adjuvant Therapy in Chinese Patients with Stage IIIA EGFR Mutation-Positive Non-Small-cell Lung Cancer (EVAN): a Randomised, Open-Label, Phase 2 Trial.

Erlotinib As Neoadjuvant Treatment in Patients with Iiia-N2 Non-Small Cell Lung Cancer(Nsclc) with Activating Epidermal Growth Factor Receptor (egfr) Mutation (nct01217619, Estern)

Erlotinib As Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Prospective, Single-Arm, Phase II Study

Adjuvant Treatments for Surgically Resected Non–Small Cell Lung Cancer Harboring EGFR Mutations

Improved survival from early combined radiotherapy: A phase II clinical study and underlying mechanisms of delaying EGFR-TKI acquired resistance in patients with advanced lung cancer.

CTONG1104: Adjuvant Gefitinib Versus Chemotherapy for Resected N1-N2 NSCLC with EGFR Mutation-Final Overall Survival Analysis of the Randomized Phase III Trial 1 Analysis of the Randomized Phase III Trial.

Updated Overall Survival and Exploratory Analysis From Randomized, Phase II EVAN Study of Erlotinib Versus Vinorelbine Plus Cisplatin Adjuvant Therapy in Stage IIIA Epidermal Growth Factor Receptor+ Non-Small-Cell Lung Cancer

Does Neoadjuvant Targeted Therapy Provide an Opportunity for Resectable EGFR-mutant Lung Cancer: a Real-World Retrospective Study

OA06.04 Postoperative Chemotherapy Use and Outcomes from ADAURA: Osimertinib As Adjuvant Therapy for Resected EGFR Mutated NSCLC

Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 <i>EGFR</i>-Mutant Non–Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study